LantHEUS HOLDINGS INC (NASDAQ:LNTH) Beats Q3 Revenue Estimates and Raises Full-Year Guidance

Lantheus Holdings Inc (NASDAQ:LNTH) reported third-quarter financial results that surpassed analyst revenue expectations, though adjusted earnings per share came in slightly below consensus estimates. The radiopharmaceutical company's performance and updated corporate guidance have drawn investor attention, reflected in significant pre-market stock movement.

Quarterly Performance Versus Estimates

The company reported Q3 2025 worldwide revenue of $384.0 million, representing a 1.4% year-over-year increase. This figure exceeded analyst expectations of $370.6 million. However, the company's adjusted fully diluted earnings per share of $1.27 fell slightly short of the $1.29 consensus estimate.

Key financial metrics from the quarter include:

• Revenue: $384.0 million actual versus $370.6 million estimated
• Adjusted EPS: $1.27 actual versus $1.29 estimated
• GAAP fully diluted EPS: $0.41
• Free cash flow: $94.7 million

Market Reaction and Price Action

Investors responded positively to the earnings release, with the stock showing strong pre-market gains of approximately 7.2%. This reaction suggests market participants focused more on the revenue beat and forward guidance than the slight EPS miss. The stock has demonstrated varied performance across different timeframes, with a 6.9% increase over the past month but more modest gains of 2.4% over the past week.

Updated Corporate Guidance

Lantheus provided updated full-year 2025 guidance that reflects the impact of recent acquisitions and current business outlook. The company now expects:

• Revenue: $1.49 billion to $1.51 billion (midpoint: $1.5 billion)
• Adjusted fully diluted EPS: $5.50 to $5.65

This revenue guidance midpoint sits approximately 1.1% above analyst estimates of $1.48 billion, while the EPS guidance range brackets current expectations. The updated forecast incorporates contributions from the recently acquired Life Molecular Imaging business.

Business Highlights and Strategic Developments

Beyond the financial results, Lantheus announced several significant developments during the quarter. The company is undergoing a leadership transition with CEO Brian Markison set to retire at year-end, while the board conducts a search for his successor. On the product development front, the company received multiple PDUFA dates from the FDA for key pipeline assets, including:

• LNTH-2501 for neuroendocrine tumors (March 29, 2026)
• MK-6240 for Alzheimer's disease diagnostics (August 13, 2026)
• New formulation of piflufolastat F 18 PSMA PET imaging agent (March 6, 2026)

The company also completed its acquisition of Life Molecular Imaging in July and repurchased $100 million of common stock during the quarter.

Product Performance Breakdown

Lantheus reported mixed results across its product portfolio:

• PYLARIFY sales decreased 7.4% to $240.6 million
• DEFINITY sales increased 6.3% to $81.8 million
• Recently acquired Neuraceq contributed $20.4 million in revenue

The company ended the quarter with $382.0 million in cash and cash equivalents, having deployed significant capital for acquisitions and share repurchases throughout the period.

For more detailed earnings information and future estimates, view the complete earnings and estimates data for Lantheus Holdings.

Disclaimer: This article is not investment advice. Investors should conduct their own research and consider their individual financial circumstances before making investment decisions.